[Intervention in the renin-angiotensin and kallikrein-kinin systems. Pharmacologic basis of the action of ACE inhibitors].
Linz
Wolfgang
W
Aventis Pharma Deutschland GmbH Gebäude G 879 65926 Frankfurt am Main. Andreas.Busch@aventis.com
Busch
Andreas E
AE
D000804:Angiotensin II / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D016234:Kallikrein-Kinin System / Q000187:drug effects*; D007703:Peptidyl-Dipeptidase A / Q000235:genetics / Q000378:metabolism; D011110:Polymorphism, Genetic; D012084:Renin-Angiotensin System / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D007703:Peptidyl-Dipeptidase A